TCR and CD16-mediated target-cell recognition by CD4⁺ HLA-DPB1*0401–specific cytolytic T-cell clones. Non-transduced and transduced T-cell clones were tested against ⁵¹Cr-labeled HLADPB1*0401-negative or -positive BLCLs. ADCC activities were assessed in presence of either rituximab (anti-CD20, 2 μg/mL) or herceptin (anti–HER-2, 10 μg/mL) as negative controls. Results are expressed as percentage of specific lysis (effector-to-target ratio = 30:1, mean of triplicate). For clone 31, ▪ and □ represent 2 independent experiments.